Top 20 RNAi Therapeutic Companies Based on 2022 R&D Expenditure
PharmaShots
APRIL 25, 2023
In 2019, Mallinckrodt entered into a collaboration agreement with Silence Therapeutics to develop and commercialize RNAi therapeutics to treat life-threatening unmet diseases. Through the 2019 agreement, Mallinckrodt received the exclusive worldwide license to Silence’s SLN500. R&D Expenditure: $85.1M
Let's personalize your content